海普瑞(09989.HK)子公司治療肺炎藥物完成大中華區III期首例患者給藥
海普瑞藥業(09989.HK)公布,旗下控股子公司深圳市瑞迪生物醫藥,就AR-301作為抗生素輔助治療金黃色葡萄球菌引起的呼吸相關性肺炎的III期大中華區藥品臨床試驗已經完成首例患者給藥。
這項大中華區關鍵性試驗預計將招募來自合共26個臨床站點的30名患者。本研究的主要臨床有效性目標為評估第21天時單獨SOC治療與SOC和AR-301-002聯合治療間臨床治愈率的差異。公司與領域內的臨床專家一起定義了嚴格的臨床治愈標準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.